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Abstract
Prolonged exposure to cigarette smoking is the main risk factor for
emphysema, a component of chronic obstructive pulmonary diseases
(COPDs) characterized by destruction of alveolar walls. Moreover,
smoking is associated with pulmonary artery remodeling and
pulmonary hypertension, even in the absence of COPD, through as
yet unexplained mechanisms. In murine models, elevations of intra-
and paracellular ceramides in response to smoking have been
implicated in the induction of lung endothelial cell apoptosis, but the
role of ceramides in human cell counterparts is yet unknown. We
modeled paracrine increases (outside-in) of palmitoyl ceramide
(Cer16) in primary human lung microvascular cells. In naive cells,
isolated from nonsmokers, Cer16 signiﬁcantly reduced cellular pro-
liferation and induced caspase-independent apoptosis via mito-
chondrial membrane depolarization, apoptosis-inducing factor
translocation, and poly(ADP-ribose) polymerase cleavage. In these
cells, caspase-3 was inhibited by ceramide-induced Akt phosphory-
lation, and by the induction of autophagic microtubule-associated
protein-1 light-chain 3 lipidation. In contrast, cells isolated from
smokers exhibited increased baseline proliferative features associated
with lack of p16INK4a expression and Akt hyperphosphorylation.
These cells were resistant to Cer16-induced apoptosis, despite
presence of both endoplasmic reticulum stress response and mito-
chondrial membrane depolarization. In cells from smokers, the
prominentup-regulationofAktpathways inhibited ceramide-triggered
apoptosis, and was associated with elevated sphingosine and high-
mobility groupbox1, skewing the cell’s response toward autophagy and
survival. In conclusion, the cell responses to ceramide aremodulated by
an intricate cross-talk between Akt signaling and sphingolipid
metabolites, and profoundly modiﬁed by previous cigarette smoke
exposure, which selects for an apoptosis-resistant phenotype.
Keywords: sphingolipids; chronic obstructive pulmonary disease;
apoptosis; autophagy; high-mobility group box 1
Clinical Relevance
The main ﬁnding that chronic exposure to cigarette smoking
changes the phenotype of human lung microvascular
endothelial cells, selecting for an apoptosis-resistant and more
proliferative population, may be relevant to the pathogenesis
of chronic obstructive pulmonary disease (COPD). This
hyperproliferative phenotype resembles that of endothelial cells
isolated from lesions of idiopathic arterial pulmonary
hypertension. Whereas lung microvascular endothelial cell
apoptosis has been implicated in the initiation and progression
of emphysema, the adaptation to apoptosis or surviving cells
may contribute to the development of pulmonary vascular
remodeling in COPD.
Cigarette smoke (CS) exposure is one of the
main risk factors of chronic obstructive
pulmonary disease (COPD), a syndrome
with many phenotypes, including
emphysema. The latter is characterized by
increased apoptosis of cells comprising the
alveolar wall. This destructive process
particularly targets lung microvascular
endothelial cells and alveolar epithelial cells,
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as noted in human lung samples or animal
models of disease (1). Previous work in
murine models indicated that endothelial
and epithelial cell apoptosis leading to
emphysema is due to up-regulation of
ceramides, sphingolipid species with
pleiotropic biological actions (2–5).
Furthermore, lungs of human subjects with
emphysema or even smokers that have not
yet developed the disease exhibit increased
lung ceramide levels (2, 6), together with
increased apoptosis and autophagy (7–10).
Although these ﬁndings implicate ceramide
elevations in the lungs of smokers as
potential triggers or mediators of
endothelial cell apoptosis, this hypothesis
has not yet been tested in human cells. In
addition, it is not known if endothelial cells
challenged with ceramide transition
through autophagy before undergoing
apoptosis.
Autophagy, a mechanism of cellular
constituent recycling, can be triggered
during endoplasmic reticulum (ER) stress
(11) or by increases in the danger-
associated signaling molecule high-mobility
group box 1 (HMGB1) (12), as an attempt
to maintain cell survival. Depending on the
cell’s adaptive or repair capacity, autophagy
may be followed by apoptosis. However, the
key molecular events that determine the
switch from autophagy to survival or
apoptosis during exposure to CS in general,
or to ceramides in particular, are not
known. This is of particular importance, as
aberrant lung endothelial cell responses
may contribute to pulmonary vascular
remodeling frequently observed in COPD.
A better understanding of the effects of
ceramide on human lung endothelial cell
survival, autophagy, and apoptosis
parameters is therefore needed.
We investigated the response of
primary human lung microvascular
endothelial cells (LMVECs) to long-chain
palmitoyl ceramide (Cer16), because this is
one of the most abundant lung ceramides
(6), which is associated with lung
endothelial cell apoptosis in vivo and
in vitro (13). Cells exposed to exogenous
ceramide trigger further endogenous
ceramide production via the de novo
synthesis pathway (14), which requires the
action of the dihydroceramide (DHC)
desaturase on DHC, the immediate
precursor of ceramide. DHC is itself an
active metabolite with antiproliferative
activities (15). Through the action of
ceramidases, endogenous ceramides can be
further metabolized to sphingosine (SPH)
and SPH 1-phosphate (S1P). Although S1P
has well characterized prosurvival
functions, the effect of SPH during cellular
adaptation to stress is not known.
We demonstrate that primary human
lung endothelial cell responses to Cer16 are
profoundly modulated by previous CS
exposure, and that, unlike murine cells, their
survival responses are very robust. As
expected, C16 ceramide induced apoptosis
in naive endothelial cells. However, chronic
in vivo CS exposure may lead to the
selection of an apoptosis-resistant,
proliferating cell population that exhibits
up-regulation of prosurvival and stress-
response pathways, such as Akt and
HMGB1.
Materials and Methods
Materials
Ceramides with short (Cer6:0) or
intermediate (Cer16) fatty acid chain and
polyethylene glycol–conjugated ceramide
Cer16-PEG 2,000 were purchased from
Avanti Polar Lipids (Alabaster, AL). The
inhibitors used were from Sigma-Aldrich
(St. Louis, MO), with the exception of:
ZVAD-fmk (MBL, Woburn, MA); (1S,2R)-
D-erythro-2-(N-myristoylamino)-1-
phenyl-1-propanol (Biomol Int., Plymouth
Meeting, PA), and LY294002 (Calbiochem,
San Diego, CA). All antibodies were
purchased from Cell Signaling unless
otherwise stated.
Cells
LMVECs from smoker and nonsmoker
donors (Lonza, Walkersville, MD) and
human small airway epithelial cells (Lonza)
were maintained in complete culture
medium consisting of microvascular
endothelial cell growth medium and small
airway epithelial cell growth medium,
respectively, supplemented with their speciﬁc
SingleQuots (Lonza). The smoking status of
the donor was provided by the cell supplier
(Lonza).
Viability/Proliferation Assay
The assay was performed by using an
in vitro 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide (MTT) assay
(Sigma-Aldrich), as previously described.
The absorbance of formazan was measured
at 570 nm.
Apoptosis
Apoptosis was quantiﬁed by annexin
V/propidium iodide staining using an
apoptosis detection kit (R&D Systems,
Minneapolis, MN) and ﬂow cytometry
using a Cytomics FC500 cytoﬂuorimeter
with CXP software (Beckman Coulter,
Fullerton, CA).
Caspase Activity Assay
Caspase-3 activity was determined with
Apo-ONE Homogeneous Caspase-3/7
Assay (Promega, Madison, WI) using
a SpectraMax M2 plate reader (Molecular
Devices Inc., Sunnyvale, CA).
Mitochondrial Depolarization
Mitochondrial depolarization was measured
with the MitoCaptureApoptosis Detection
Kit (Calbiochem). Its main reagent is a
cationic dye that accumulates in healthy
mitochondria in aggregates that ﬂuoresce in
red. Any stimuli that alter the mitochondrial
membrane potential maintain the dye in
its monomeric form, that ﬂuoresces in
green. As positive control, cells were treated
with staurosporine (0.2 mM, 2 h), and
quantiﬁcation was done by ﬂow cytometry.
Cell Fractionation
Cell fractionation was achieved with
Mitochondria/cytosol and Nuclear/cytosol
fractionation kits (BioVision, Mountain
View, CA), according to the manufacturer’s
protocol.
Western Blotting
Equal protein amounts, as determined by
bicinchoninic acid assay protein analysis
(Pierce, Rockford, IL), were separated
by SDS-PAGE and transferred onto
a polyvinylidene diﬂuoride membrane,
followed by routine immunoblotting (16).
Immune complexes were detected using
enhanced chemiluminescence (Amersham
Biosciences, Buckinghamshire, UK),
quantiﬁed by densitometry and normalized
using speciﬁc loading controls.
Sphingolipids Determination
Lipid extraction and total lipid phosphorus
measurements were performed as
previously described (2).
Efferocytosis Assay
LMVECs were stained with Cell Tracker
Green (Invitrogen, Carlsbad, CA) and
treated with apoptosis inducers for 6 hours
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followed by coculture (5:1) with rat
macrophages for 1 hour. Efferocytosis was
quantiﬁed by ﬂow cytometry (6), and results
were expressed as efferocytosis index
(number of macrophages that engulfed
apoptotic cells 3 100).
Electron Microscopy
Samples were analyzed on a Tecnai G2 12
Bio Twin transmission electron microscope
(FEI, Hillsboro, OR) equipped with
a charge-coupled device camera (Advanced
Microscopy Techniques, Danvers, MA).
Immunocytoﬂuorescence
Cells were stained with Mitotracker Red
CMXRos (Molecular Probes/Invitrogen),
ﬁxed with paraformaldehyde (4%), and
permeabilized with 0.2% Triton X-100 in
PBS. Cells were then incubated with
apoptosis-inducing factor (AIF) antibody
(AbCam, Cambridge, MA), followed by
FITC-labeled goat anti-rabbit IgG (AbCam).
Images were obtained using an Eclipse 80I
ﬂuorescence microscope with camera and
NIS-Elements AR 3.0 15 software (Nikon,
Melville, NY).
Statistical Analysis
Statistical analysis was performed using
SigmaStat 3.5 (San Jose, CA). Differences
between groups were compared using
unpaired Student’s t test. All experiments
were done at least three times, and the data
were expressed as means (6 SEM).
Statistical difference was accepted at a P
value less than 0.05.
Results
Effects of Cer16 on Human
LMVEC Proliferation
Human primary LMVECs were obtained
from donors with a history of either never-
smoking (nonsmoker donor; also named
naive cells) or with a history of previous CS
exposure (smoker donor). Demographic
and brief clinical characteristics of the
donors are listed in Table E1 in the online
supplement. Interestingly, the baseline MTT
activity of cells from smoker donors was
noted to be 1.6-fold higher than that of cells
from nonsmokers (Figure 1a). This baseline
proliferative activity was associated with
marked divergent expression or cell cycle
control proteins. In particular, p16INK4a
(inhibitor of CDK4 family) was reduced
and retinoblastoma protein was
hyperphosphorylated in LMVECs from
smokers compared with naive cells (Figure
E1), further suggesting that cells from
smoker donors have increased proliferation
rates compared with those from
nonsmokers.
When challenged with ceramide Cer16
and compared with vehicle control, human
LMVECs exhibited marked, dose-
dependent (Figure 1b), and sustained
(Figure 1c) decreases in cell proliferation,
regardless of the smoking status of the
donor. Concentrations of ceramide that
typically induce apoptosis in murine
cultured cells or cell lines (10 mM and
higher) signiﬁcantly reduced LMVEC
proliferative activity up to 50%, even as
early as 2 hours after treatment (Figure 1c).
We next evaluated whether ceramide
reduced cell survival.
Human LMVEC Apoptotic and
Survival Responses to Cer16
Ceramide Cer16 treatment (10 mM,
6 h) caused externalization of
phosphatidylserine on LMVECs from
nonsmokers, but not on those from
smokers (Figure 2a). Neither higher
concentrations, nor prolonged exposures to
Cer16 (up to 20 mM for up to 24 h; data not
shown) or shorter chain (Cer6) ceramide
(Figure 2a) increased apoptotic annexin V
staining in endothelial cells from smoker
donors. Interestingly, the smoking-
dependent effect of ceramide on apoptosis
was cell type–speciﬁc, because both Cer16
and Cer6 signiﬁcantly increased apoptosis
in primary small airway epithelial cells
from smoker donors, but not in those from
nonsmoking donors (Figure 2b). As
a complementary functional assay of
phosphatidylserine externalization, we
assessed whether ceramide-treated
endothelial cells are engulfed
(efferocytosed) by healthy (nontreated)
macrophages. Fluorescently labeled
LMVECs from smoker or nonsmoker
donors were treated with TNF-a plus
cycloheximide for 6 hours, a treatment
known to induce endothelial cell apoptosis
via endogenous ceramide signaling (14), or
with Cer16. After treatment, endothelial
cells were incubated in a phagocytosis assay
with primary alveolar macrophages. As
expected, there was a marked increase in
macrophage-engulfed LMVECs treated
with TNF-a plus cycloheximide, indicating
that they underwent apoptosis, compared
with control LMVECs (which were not
apoptotic). Consistent with annexin V data,
the number of engulfed endothelial cells
from smokers that were treated with Cer16
was negligible and signiﬁcantly lower than
the number of engulfed Cer16-treated
naive endothelial cells (Figure E3a). Indeed,
macrophages engulfed only ceramide-
treated LMVECs from nonsmokers.
Therefore, surprisingly, measurements of
the executioner caspase activity in human
LMVECs from nonsmokers demonstrated
early (2–6 h) inhibition of caspase-3/7
activity in response to Cer16 treatment,
followed by a return to baseline levels
(Figure 2c). In a distinct fashion, ceramide-
treatment of LMVECs from smoker donors
briskly (2 h) and only modestly activated
caspase-3/7, which then remained inhibited
(Figure 2c).
Together, these results suggest that
Cer16 markedly decreases LMVEC
proliferation, inducing apoptosis in
a smoking status–dependent fashion.
Therefore, we investigated if ceramide
activated survival signaling pathways, such
as extracellular signal–regulated kinase
(ERK) 1/2 mitogen-activated protein kinase
or Akt, as these promitogenic, antiapoptotic
pathways can be engaged by ceramide in rat
lung endothelial cells (16) or in lung
macrophages (17), respectively. Ceramide
modestly and transiently activated ERK1/2
in LMVECs from smokers at 6 hours
(Figure 2 d, upper panel, Western blot and
densitometry). In contrast, Akt activation
was rapidly and signiﬁcantly (at 6 h)
induced by ceramide in naive LMVECs
(Figure 2e, upper panel, Western blot,
and lower panel, densitometry). Cells
from smokers exhibited striking levels
of Akt hyperphosphorylation even
before ceramide treatment (Figure E4a),
and ceramide had little additive
effect during the studied timeframe
(Figure 2e).
To determine the impact of survival
pathway activation on cell proliferation
and apoptosis, LMVECs were pretreated
with PD98059 and LY29400, speciﬁc
pharmacological inhibitors of ERK1/2 and
Akt, respectively. Both inhibitors decreased
cellular proliferation of unchallenged
LMVECs (Figure E2). Inhibition of ERK1/2
(Figure 2 d, lower panel) further reduced
cell proliferation in ceramide-treated cells
from smokers (Figure E2a), but did
not facilitate apoptosis (Figure 2f). In
contrast, inhibition of Akt decreased the
proliferation of ceramide-treated naive cells
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only (Figure E2b), while doubling their
apoptosis levels (Figure 2f). These results
indicate that LMVECs require ERK1/2 and
Akt activity for basal levels of cell
proliferation, regardless of smoking
exposure, and that, in naive LMVECs,
ceramide-induced Akt protects against
apoptosis, with little contribution from
ERK1/2. Moreover, inhibition of ERK had
no effect on Akt activation (Figure E4b),
inhibition of Akt stimulated ERK
phosphorylation (Figure E4c), suggesting
an interactive, compensatory prosurvival
signaling.
To investigate whether a caspase-
independent mechanism contributes to
ceramide-induced apoptosis in LMVECs,
we focused on mitochondria. Ceramide
treatment rapidly and markedly altered the
mitochondrial membrane potential in
LMVECs from nonsmokers (Figure 3a). In
agreement with the lack of executioner
caspase activation in these cells, the
mitochondrial depolarization occurred in
a caspase-independent manner, because
a general caspase inhibitor, ZVAD-fmk,
did not prevent ceramide-induced
mitochondrial membrane depolarization
(Figure E3b). LMVECs from smoker
donors depolarized mitochondria in
a caspase-independent fashion as well
(Figure E3c), albeit to a lesser degree,
compared with cells from nonsmokers
(Figure 3a). In both cell types, but especially
in smokers’ cells, Akt had an inhibitory role
on mitochondrial membrane depolarization
(Figure 3a). Cer16 treatment of naive
LMVECs, but not those from smokers,
caused AIF translocation from the
mitochondria to the nucleus, as detected
by Western blotting of cell fractions
(Figure 3b) and by immunoﬂuorescence
Figure 1. Inhibitory effects of palmitoyl ceramide (ceramide 16:0 [Cer16]) on the metabolic/proliferative activity of human lung microvascular endothelial
cells. Metabolic activity measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay in cells from nonsmoker (gray bars) and
smoker (black bars) in the following conditions: (a) untreated, 16 hours, mean 1 SEM (n = 3; *P , 0.05); (b) following vehicle (veh; polyethylene glycol
2,000) or Cer16 treatment at the indicated concentrations (6 h), fold change versus veh, mean 1 SEM (n = 3; *P , 0.05, #P , 0.005 vs. veh); or (c)
following veh, or Cer16 treatment for the indicated time in hours (10 mM), mean1 SEM (n = 3; *P, 0.0001 and #P, 0.01 vs. vehicle control; ##P, 0.05).
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Figure 2. Apoptosis and survival responses of human lung microvascular endothelial cells to Cer16. (a and b) Apoptosis measured by annexin
V/propidium iodide staining and expressed as fold increase in positive cells versus control vehicle in human lung microvascular endothelial cells (a)
compared with human small airway epithelial cells (b), both isolated from either nonsmokers (gray bars) or smokers (black bars). Cells were treated with
Cer16 or Cer6 (10 mM; 6 h), or with vehicle (PEG 2,000); mean 1 SEM (n = 4; *P , 0.05, #P = 0.006, and $P , 0.001). (c) Caspase-3 activity of
human lung microvascular endothelial cells treated Cer16 (10 mM) or vehicle (control [Ctl]) for the indicated time. Mean 1 SEM. (n = 9; *P , 0.05, #P =
0.006, and $P = 0.05. (d) Activated and total extracellular signal–regulated kinase (ERK) 1/2 measured by Western blot in lung microvascular
endothelial cells (LMVECs) lysates from nonsmoker and smoker donors after treatment with Cer16 (10 mM) or vehicle (veh) for 6 hours (upper panel,
Western blot) and 16 hours (lower panel, densitometry). Mean 1 SEM; n = 4. (e) Activated and total Akt in LMVEC lysates treated with either Cer16
(10 mM) or vehicle for 6 hours (upper panel showing Western blot and lower panel showing densitometry). Mean 1 SEM (n = 4; two-way ANOVA
showing P , 0.05 for both Cer treatment and smoking status). (f) Effect of ERK1/2 or Akt inhibition on LMVEC apoptosis measured by annexin V/PI
staining in cells from nonsmoker donors. Cells were pretreated (1 h) with either PD98059 (10 mM) or LY294002 (30 mM) followed by Cer16 (10 mM, 2 h).
Results are expressed as fold change versus Cer16. Mean 1 SEM (n = 3; *P = 0.01, #P , 0.0001). P-Akt, phosphorilated serine/threonine-specific
protein kinase; P-ERK, phosphorilated extracellular signal–regulated kinase; Ser, serine; Thr, threonine.
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(Figure 3c). Consistent with AIF
translocation, ceramide treatment
cleaved poly(ADP-ribose) polymerase
(PARP) only in LMVECs from nonsmokers
(Figure 3d). In contrast, in LMVECs
from smokers, ceramide-induced PARP
cleavage was noted only in the presence
of Akt inhibitor (Figure 3d). These
results suggest that ceramide induces
caspase-independent mitochondrial
activation, AIF translocation, and PARP
cleavage apoptosis in LMVECs from
nonsmokers. In contrast, LMVECs from
smokers are more resistant to ceramide-
induced apoptosis, in large part via Akt
activation.
Human LMVEC Autophagy in
Response to Cer16
The conversion via lipidation of
microtubule-associated protein 1 light-
chain 3 (LC3) from LC3-I (free form) to
LC3-II (membrane-bound form) is a key
step in the induction of autophagy in
mammalian cells. Primary human LMVECs
displayed basal levels of LC3-II expression
in culture conditions of low serum–
containing media (Figure 4a). The
conversion of LC3-I to LC3-II was
increased by Cer16, regardless of the
smoking status of the donor (Figure 4a).
This effect was noted as early as 6 hours
after ceramide treatment (Figure 4b), and
persisted for 16 hours (Figures 4a and 4b).
The autophagy inhibitor 3-methyladenine
(3-MA), although not affecting LC3-II
levels in untreated cells, inhibited ceramide-
induced LC3-I to LC3-II conversion
(Figure 4a). Treatment with ZVAD-fmk did
Figure 3. Mitochondria changes in human lung microvascular endothelial cells treated with Cer16. (a) Mitochondria depolarization in cells treated with
Cer16 (10 mM, 6 h) or vehicle (Veh) and effect of Akt inhibitor LY294002 (30 mM, 1 h pretreatment). Mean1 SEM (n = 3; *P, 0.05, #P, 0.001, $P = 0.05).
(b and c) Apoptosis-inducing factor (AIF) translocation from mitochondria to nucleus detected by Western blot (b) in respective cellular subfractions
of cells treated with Cer16 (10 mM; for the indicated time in hours) or its Veh (PEG 2000; Ctl1) compared with staurosporine (Stauro; 0.2 mM, 2 h) or its
Veh (Ctl2). Loading controls for each subcellular fraction, voltage-dependent anion channel (VDAC1) and TATA-binding protein (TBP), were detected in
the lower lanes. Densitometry of AIF expression normalized by loading control is indicated numerically in between lanes. (c) Representative
fluorescence micrographs of cells immunostained for AIF (FITC-labeled). Mitochondria are stained in red (MitoTracker Red) and nuclei in blue with 49,6-
diamidino-2-phenylindole (DAPI) after treatment with Cer16 (10 mM) or Veh; scale bar, 50 mm. (d) Detection of cleaved poly(ADP-ribose) polymerase
(PARP) in total protein lysates of cells: untreated, grown in regular full serum–containing media (FM); or treated with Veh or Cer16 (10 mM, 6 h), and either
Akt inhibitor (30 mM LY294002; 1 h pretreatment) or autophagy inhibitor, 3-methyladenine (3-MA; 5 mM, 1 h pretreatment). Vinculin expression was used
as loading control.
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not alter ceramide-induced autophagy
(Figures 4a and E5e). Autophagy was
conﬁrmed by electron microscopy, which
showed an increased number of
autophagosomes after ceramide treatment
(Figure 4b), without impairment of the
autophagic ﬂux (Figures E5a–E5c). Electron
microscopy images of ceramide-induced
autophagy unveiled concomitant ER stress,
characterized by swelling of the ER lumen
(Figure 4b). Ceramide-induced ER stress
was conﬁrmed biochemically by Western
blotting for phospho- and total eukaryotic
translation initiation factor 2a (eIF2a).
Ceramide treatment increased eIF2a
phosphorylation in all LMVECs (Figures 4c
and E4d). Inhibition of autophagosome
formation with 3-MA modestly increased
phospho-eIF2a levels in ceramide-treated
cells, suggesting that autophagy may partly
attenuate ER stress (Figures 4c and E4d).
The effect of caspase inhibition on ER stress
was equivocal, having no effect in
ceramide-treated naive LMVECs, while
enhancing it in LMVECs from smokers
(Figure 4c).
Interestingly, only in naive LMVECs,
inhibition of autophagy with 3-MA
protected against mitochondrial
depolarization (Figure 5b) and PARP
cleavage (Figure 3d), while inducing
caspase-3 activation (Figure 5a), indicating
that induction of autophagy is a
prerequisite for caspase-3–independent
apoptosis of these cells, and that its
inactivation compels the cells into caspase-
3–dependent apoptosis.
To further understand the complex
interrelationship between autophagy and
apoptosis, we investigated the involvement
of HMGB1, a danger-associated molecular
pattern and ligand of the receptor for
advanced glycation end products found to be
elevated in the blood, bronchoalveolar lavage
ﬂuid, and lung tissue of patients with COPD
(18 and 19). HMGB1 involvement in
autophagy (20) and apoptosis (21, 22) has
been recently described. Moreover, its
intracellular overexpression was recently
correlated with angiogenesis (23) and
proliferation (24). Because LMVECs from
smokers exhibited enhanced autophagy
rather than apoptosis in response to
ceramide treatment and were more
proliferative at baseline, we investigated if
prosurvival pathways modulated HMGB1
levels in these cells. HMGB1 was noticeably
increased in LMVECs from smokers
compared with nonsmokers (Figures 5c and
E4f). Ceramide treatment increased HMGB1
at 6 hours (Figures 5c and E4f). Neither
protein synthesis inhibition, nor ERK1/2
inhibition altered HMGB1 expression
(Figure 5c). Similarly, HMGB1 levels were
not affected by caspase inhibitors or 3-MA
(data not shown). Instead, HMGB1
expression in cells from smokers, both at
baseline and in response to ceramide, was
dependent on Akt phosphorylation, because
Akt inhibition markedly reduced HMGB1
levels, concomitant with diminishing LC3
lipidation (Figure 5c). These data suggest the
involvement of HMGB1 in the apoptosis-
resistant phenotype induced by chronic
smoking.
Involvement of Endogenous
Sphingolipids in LMVEC Autophagy
Exogenously administered ceramide is
known to exert biological effects in large
part due to stimulation of endogenous
ceramides synthesis. The effect of outside-in
ceramides on other metabolites that may
impact cell proliferation and survival, such
as DHCs, SPH, or S1P, is not well described.
We determined sphingolipid levels in
LMVECs by tandem mass spectrometry. As
expected, Cer16 treatment markedly
elevated total ceramides in LMVECs
(Figure 6a), accompanied by signiﬁcant,
albeit less robust, increases in DHC
(Figure 6b). The DHC content in cells from
nonsmokers was under the control of Akt,
as Akt inhibition markedly increased DHC
levels in these cells, with negligible effect of
ceramide levels, suggesting that Akt activity
may be linked to DHC desaturase activity,
which converts DHC to ceramide.
Cer16 also elevated downstream
production of SPH levels in cells from
smokers, which already had elevated SPH
levels, but not in naive cells (Figure 6c). The
increase in SPH, which indicates activation of
ceramidases, was also inﬂuenced by Akt
activity. Interestingly, SPH levels were
modiﬁed by treatment with the autophagy
inhibitor, 3-MA, in all cells (Figure 6c).
Although Cer16 up-regulated SPH, this was
not translated into increased S1P levels;
rather, ceramide-treated cells had less S1P
content, indicating concomitant lack of
activation or even inhibition of SPH kinases
(Figure 6d). It was surprising that LMVECs
from smokers had reduced S1P levels
compared with those from nonsmokers
(Figure 6d), given their propensity for
increased survival (Figure 6e). To further
explore the signiﬁcance of SPH production,
we used the ceramidase inhibitor, (1S,2R)-D-
erythro-2-(N-myristoylamino)-1-phenyl-1-
propanol, and measured the MTT activity of
LMVECs. Inhibition of ceramidase
diminished MTT activity in untreated and
ceramide-treated LMVECs (Figure 6e),
reduced HMGB1 levels, and reduced LC3
lipidation (Figure 6f), indicating that SPH
may contribute to the prosurvival adaptation
of LMVECs.
Discussion
The synthesis of ceramide species at the
plasma membrane increases their
paracellular bioavailability where they exert
paracrine and/or autocrine effects. Our
results show that lung endothelial cellular
responses to a ceramide-rich milieu include
a general decrease of cell metabolism and
proliferation, and induction of autophagy
with or without apoptosis, depending on the
smoking exposure history of the donor
(Figure 7). These ﬁndings may relate to the
pathogenesis of emphysema, a disease
typically associated with intermittent, but
chronic, exposure to cigarette smoking,
which increases both intra- and paracellular
ceramides. The fact that ceramide induced
the expression of ER stress response
markers and the up-regulation of HMGB1
and Akt pathways, which are both detected
in human COPD lungs, indicates potential
relevance of our ﬁndings to human disease.
Because active challenges of human lung
structural cells cannot be performed in vivo,
we have employed a reductionist approach
to directly assess responses to extracellular
ceramide rather than to CS extract. This
approach allowed the study of speciﬁc
responses to the sphingolipid, as CS
contains more than 2,000 chemicals,
and the precise dosing and exposure time
in cell culture that mimics human exposure
is not known. Furthermore, COPD is
known to progress even after affected
individuals stop smoking. For these
reasons, the effect of chronic CS exposure
was investigated by comparing primary
cells isolated from individuals with
a history of cigarette smoking to naive cells
isolated from nonsmokers. To our
knowledge, this is the ﬁrst direct
comparison of this kind.
We previously determined ceramide
species in human acellular bronchoalveolar
lavage as a window into the content of
ceramide in lung environment. Although
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Figure 4. Autophagy and endoplasmic reticulum (ER) stress in human lung microvascular endothelial cells treated with Cer16. (a) Western blot of
microtubule-associated protein-1 light-chain 3 (LC3) -I and LC3-II and vinculin (as loading control) in cells treated with Cer16 (10 mM, 16 h) or Veh, and
effect of general caspase inhibitor, known commercially as ZVAD-fmk (0.1 mM, 1 h pretreatment) or autophagy inhibitor 3-MA (5 mM, 1 h pretreatment).
(b) Representative electron microscopy images of cells after treatment with Cer16 or Veh for 6 or 16 hours. Noted are: nuclei (n), ER swelling (arrowheads,
lower panel), autophagosomes (magnified in lower panel inset, arrows), and autophagosome–lysosome fusion (magnified in upper panel inset, arrow).
(c) Western blot of phospho- and total eukaryotic translation initiation factor 2a (eIF2a) in cells similarly treated as in (a). Cells were treated with Cer16 or Veh
control (PEG 2,000; 10 mM, 16 h) and pretreated with ZVAD-fmk (0.1 mM, 1 h) or 3-MA (5 mM, 1 h). b-tubulin was used as loading control.
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the lung contains a vast range of ceramide
species, one of the most abundant species is
Cer16 (6). CS up-regulates Cer16 in the
lung, and increasing Cer16 in the lungs of
mice causes both endothelial and epithelial
cell apoptosis in vivo (25). Primary human
lung endothelial cells proved to be much
more resistant to ceramide-induced cell
death, associated with prompt induction of
Akt signaling by ceramide. Furthermore,
smoking potentially selected for a surviving
cell population with higher proliferative
capacity. This phenotype is reminiscent to
that of endothelial cells isolated from
patients with pulmonary arterial
hypertension (PAH), where, after an initial
apoptotic insult, there is selection of
hyperproliferative and apoptosis-
recalcitrant cells (26). Whereas typical
plexiform lesions from idiopathic PAH
are only rarely described in COPD, up to
70% of patients with COPD go on to
develop PAH and pulmonary artery
remodeling, features directly associated
with worse prognosis and disease
exacerbations (27). In addition, our
results support ﬁndings in vivo of effects
of smoking on pulmonary vasculature
remodeling even in the absence of
airspace destruction (28).
In lung cancer, p16INK4a is
transcriptionally silenced through aberrant
promoter hypermethylation due to
cigarette smoking (29). It is possible that
a similar mechanism occurs in endothelial
cells exposed to chronic smoking, and
may be responsible for the state of
Akt and retinoblastoma protein
hyperphosphorylation. The Akt signaling
pathway was in large part responsible for
endothelial cell fate, overall rendering the
cells resistant to apoptosis induced by
ceramides either directly or indirectly,
during TNF-a and cycloheximide
treatment (30). Despite resistance to
Figure 5. Autophagy and apoptosis interactions in human lung microvascular endothelial cells treated with Cer16. (a and b) Apoptosis measured by caspase-3
activity (a) or mitochondrial depolarization (b) in cells treated with Cer16 (10 mM; 2 hours in [a] and indicated time in [b]) or Veh, and effect of autophagy
inhibitor, 3-MA (5 mM, 1 h pretreatment). Mean 1 SEM (n = 4, *P, 0.05). (c). Levels of high-mobility group box 1 (HMGB1) or LC3-I and LC3-II measured by
Western blot in cells treated with Cer16 (10 mM, for the indicated time) or Veh and either protein synthesis inhibitor, cycloheximide (CHX; 1 mg/ml, 1 h
pretreatment), ERK1/2 inhibitor, PD98059 (PD; 50 mM, 1 h pretreatment), or Akt inhibitor LY294002 (LY; 30 mM, 1 h pretreatment).
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Figure 6. Modulation of intracellular sphingolipids by Cer16 in human lung microvascular endothelial cells. (a–d) Abundance of indicated sphingolipid
species measured by combined liquid chromatography–tandem mass spectrometry in cells treated with Cer16 (10 mM, 2 h in [a and b]; 6 h in [c and d]) or
Veh, and effect of Akt inhibitor LY294002 (30 mM, 1 h pretreatment) or autophagosome formation inhibitor, 3-MA (5 mM, 1 h pretreatment). Mean 1
SEM (n = 2; *P , 0.05, #P , 0.005). (e) Cell metabolic activity assessed by MTT assay in cells treated with Cer16 (10 mM, 24 h) or Veh, and effect of
ceramidase inhibitor, (1S,2R)-D-erythro-2-(N-myristoylamino)-1-phenyl-1-propanol (MAPP; 1 mM, 2 h pretreatment). Mean 1 SEM (n = 3; *P , 0.001,
#P , 0.05). (f) HMGB1, LC3-I, and LC3-II expression detected in protein lysate from cells treated with Cer16 (10 mM, 6 h) or Veh, and effect of
MAPP. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as loading control. Densitometry of HMGB1 expression normalized by
loading control is indicated numerically in between blots. S1P, sphingosine 1-phosphate; SPH, sphingosine.
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apoptosis, these cells displayed markedly
decreased metabolic/proliferative rates,
possibly via ceramide-induced regulation of
cell cycle checkpoints. The signiﬁcance to
the pathogenesis of COPD and associated
vascular abnormalities can only be
speculated. It is possible that excessive
apoptosis of vulnerable cells contributes to
the typical alveolar wall destruction in
emphysema. Because microvascular
endothelial cells have been suggested to
function as progenitor cells (31), and may
therefore be involved in tissue repair, it is
possible that the inhibitory effect of
ceramide on their proliferative and
metabolic activities is detrimental to tissue
repair. On the other hand, exuberant
proliferation of endothelial cells
from smokers may lead to development
of PAH in these lungs, and the inhibitory
effect of ceramide on microvascular
endothelial cell proliferation in this
context may actually be beneﬁcial. These
scenarios remain to be answered in
experimental models.
This study corroborates previous
reports of increased ER stress in the setting
of CS-induced emphysema (32), and
highlights that endothelial cells also display
this type of stress response to ceramide.
Recent studies identiﬁed contributions of
ceramides to ER stress and mitochondrial
membrane potential alterations associated
with apoptosis in insulin-secreting cells
(33). In human lung endothelial cells,
however, ceramide triggered ER stress
together with prominent induction of
autophagy, which, in turn, protected
against further ER stress and minimized
apoptosis. The mechanism by which
ceramide induces autophagy and its full
characterization in endothelial cells is not
well described. Ceramide was shown to
trigger homeostatic autophagy by
decreasing nutrient transporter proteins, thus
causing severe bioenergetic stress (34). In
addition, both ER function (35) and
autophagy (36, 37) can be controlled by
various sphingolipid metabolites induced by
ceramide. It is well established that exogenous
(outside-in) ceramides activate endogenous
sphingolipid production via de novo
synthesis, which increases the production of
the intermediate metabolite, DHC. Although
much less abundant than ceramide, DHC
itself can inhibit cell proliferation (15) and
trigger autophagy. Our results suggest that
DHC and SPH homeostasis might be
regulated by Akt, and that cells respond to
autophagy by further increasing SPH levels.
Intracellular SPH did not trigger apoptosis; it
rather appeared to be involved in autophagy
and proliferative responses of cells exposed to
ceramide.
Our work reveals a previously
unappreciated link between ceramide, SPH,
and HMGB1 in endothelial cell autophagy
and apoptosis. In addition, knowing that
HMGB1 conveys immunogenicity of the
dying cell (38), the elevation of HMGB1 in
lung endothelial cells challenged with
ceramide may put forward the hypothesis
that the ceramide–SPH–HMGB1 pathway
participates in the autoimmune features of
emphysema pathogenesis. Recent studies
showed that HMGB1 promotes proliferation
through Akt signaling pathway in hepatic
stellate cells (39). Moreover, in mouse
mesangial cells, HMGB1 increased the
proliferation index, and the process was
accompanied by down-regulation of
p16INK4a (40). In turn, p16INK4a was
demonstrated to be an efﬁcient inhibitor of
breast stromal ﬁbroblasts proangiogenic
effects through inhibition of Akt (41).
Because LMVECs from smokers exhibit no
p16INK4a accompanied by up-regulation of
Figure 7. Schematic summarizing findings of Cer16 effect on human LMVECs isolated from
nonsmokers compared with those isolated from smokers. Human naive LMVECs respond to
ceramide by increasing ER stress and mitochondrial depolarization, which is associated with AIF-
mediated, caspase-independent (Akt-inhibited caspases) apoptosis and autophagy (top). Chronic
exposure to cigarette smoke (CS) is associated with Akt hyperphosphorylation and increased
levels of SPH, which contributes to robust induction of autophagy associated with high HMGB1
levels, and which, together, contribute to develop an apoptotic-resistant phenotype (bottom).
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HMGB1 and Akt hyperphosphorylation, we
propose that the increased levels of SPH
induced by chronic smoking may be related
to Akt activation through HMGB1.
From a cell mass perspective, the
decreased alveolar surface area in human
emphysema lungs is the net results of an
imbalance of alveolar structural cell
apoptosis (excessive) and proliferation (7)
(insufﬁcient or ineffective). Murine in vivo
models and cultured primary lung
endothelial cells showed that ceramides
activate executioner caspases-3/7 (2, 3, 14).
In contrast, in naive primary human lung
microvascular cells, palmitoyl-ceramide
caused an unexpected immediate inhibition
of caspase-3/7 activity, due to activation of
autophagy and Akt. While in naive cells,
the ceramide-induced Akt phosphorylation
inhibited executioner caspases, but still
allowed ceramide to induce apoptosis in
a caspase-independent manner; the
hyperphosphorylated Akt levels in cells
from smokers inhibited ceramide-induced
apoptosis altogether. Although solubilized
palmitoyl-ceramide has been shown to
induce a potent release of cytochrome c
when added to mitochondrial suspensions
(42) and ATP depletion followed by
collapse of the inner mitochondrial
membrane potential (43), the caspase-
independent apoptosis via AIF
translocation has not been previously
appreciated in lung endothelial cells. Our
data suggest that the baseline Akt
hyperphoshorylation in cells from smokers
contributes to a phenotype of resistance to
proapoptotic insults, such as ceramide,
including inhibition of caspase activation
and that of mitochondria-related events
that cause apoptosis. Although the “de
novo” Akt phosphorylation induced by
ceramide treatment in nonsmokers’ cells is
exerting similar anticaspase effects, it is not
sufﬁcient to inhibit mitochondria-related
apoptosis. This suggests that mitochondrial
tolerance to ceramide requires a different
timing or context induced by the baseline
Akt phosphorylation.
In conclusion, our study identiﬁes
exposure to CS as an important determinant
of subsequent responses to stress, such
as that induced by paracellular palmitoyl-
ceramide. Human LMVECs respond to
ceramide by potently up-regulating survival
pathways, triggering ER stress, blocking
cell proliferation, and inducing autophagy
and caspase-independent AIF-mediated
apoptosis, via a cross-talk among ERK1/2,
Akt activation, and sphingolipid metabolite
accumulation. Chronic exposure to CS
changes the phenotype of these cells,
selecting for a more proliferative population,
with baseline alterations in p16INK4a
expression, and Akt hyperphosphorylation,
through yet-undetermined mechanisms.
This phenotype renders cells from smokers
less likely to die by apoptosis from
palmitoyl-ceramide exposure, despite
potent mitochondrial activation but
perhaps due to robust induction of
autophagy associated with high HMGB1
levels. This study prompts future in vivo
investigations to determine the implication
of these phenotypes to disease initiation
and progression in the lungs of smokers,
and to the development of pulmonary
hypertension in this setting. Furthermore,
our results indicate a complex cross-talk
between ER stress, autophagy, and
apoptosis, which is, in part, mediated by
the intracellular changes in sphingolipid
metabolites, and highlight the importance
of the ceramide species- and disease-
speciﬁc context for the ultimate fate of
multi-input signaling pathways. n
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